Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1

Interventions

Paclitaxel 4tocilizumab 2pembrolizumab 2zansecimab 1tivozanib 1temsirolimus 1spartalizumab 1ridaforolimus 1parsaclisib 1olaparib 1obinutuzumab 1motesanib diphosphate 1liposomal doxorubicin 1itacitinib 1epacadostat 1durvalumab 1birinapant 1atezolizumab 1Vertebroplasty 1Temozolomide 1TAK-981 1Ramucirumab 1Panobinostat 1Oxaliplatin 1Leucovorin 1Kyphoplasty 1IT-101 1INCB039110 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Solid Tumors × IT-101 × Clear all
NCT02648711 2020-05-28

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Lumos Pharma

Phase 1 Terminated
41 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡